GBA Presents: RADIO SAVANT-!

Airbnb to roll out 'extensive set of improvements' Wednesday, says CEO 18:34 ABNB Airbnb CEO Brian Chesky said in a tweet: "I've heard your feedback about how to improve Airbnb. Tomorrow, we're rolling out our most extensive set of improvements ever." Reference Link

Terex price target raised to $50 from $47 at Baird » 17:43 TEX

Power Integrations management to meet virtually with Benchmark » 16:49 POWI

Kanzhun initiated with an Outperform at Macquarie 16:11 BZ Macquarie initiated coverage of Kanzhun with an Outperform rating and $24.10 price target.

Ford backs FY23 adjusted EBIT view of $9B-$11B 16:07 F Ford is maintaining the full-year 2023 performance expectations that the company first articulated in early February: for adjusted EBIT of $9 billion to $11 billion and adjusted free cash flow of about $6 billion. Additionally, the company reaffirmed 2023 segment-level EBIT expectations: about $7 billion for Ford Blue, up modestly from last year; a full-year loss of about $3 billion for Ford Model e; and EBIT approaching $6 billion for Ford Pro, which would be nearly twice its 2022 earnings.

Estee Lauder cites headwinds facing Asia travel retail for lowered FY outlook » 06:57 EL
 
Flowserve price target raised to $40 from $37 at Mizuho 06:55 FLS Mizuho

OneSpaWorld sees Q2 revenue $185M-$190M, consensus $171.72M 06:52 OSW Sees Q

OneSpaWorld sees FY23 revenue $710M-$730M, consensus $687.54M 06:51 OSW

OneSpaWorld reports Q1 adjusted EPS 13c, consensus 11c

MoonLake Immunotherapeutics, SHL Medical announce collaboration 06:52 MLTX
 
“I’d prefer to do what’s called the hawkish pause, not raise but signal that we are in a tightening stance, because I actually think the banking situation may well be more serious than we currently understand,” Kaplan, whose career has also included time as a senior executive at Goldman Sachs Group Inc., said in a Bloomberg Television interview.

Kaplan went on to say that bank equities have been marked down solely because of their over-investment in US Treasuries, while the credit phase, which is “normally more serious,” is yet to unfold.
 

Carl Icahn’s Wealth Plunges $10 Billion on Hindenburg Short-Seller Report
60
31094daed835499f3898b44fe73892ff

Carl Icahn’s Wealth Plunges $10 Billion on Hindenburg Short-Seller Report
 
The Daily Wire and host of the Ben Shapiro Show podcast, now owns 4.8% of Oramed Pharmaceuticals Inc., according to regulatory filings published late Monday. That makes him the company’s biggest shareholder, according to data compiled by Bloomberg.

Shapiro’s investment comes after Oramed’s stock price collapsed by 80% due to its failure in January in a years-long effort to develop a method to deliver insulin to diabetics orally, rather than by injection. The company has since said it would “explore potential strategic alternatives” including an acquisition, merger, business combination, or other transaction.

Oramed rose 8.4% to $2.66
 

‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $10--- ONE IS THE POOP STOCK!

CERS
-8.09%<----------:caution:
b50a0c42d79f5b1a78560e1bff70a3ed





Cerus Corporation (CERS)

It’s well-known that Cathie Wood has a penchant for disruptors and those are often found at the junction where health and tech meet. This is where you can find medical device company Cerus, whose goal is to be the standard of care in blood transfusion medicine.

The Intercept Blood System, which the company makes and sells, is intended to destroy blood-borne infections in platelets and plasma – components of donated blood. For these two blood components, the product is the sole pathogen reduction system boasting both a CE mark and FDA approval.

Shares, however, took a bit of a beating earlier this year after the company released disappointing revenue guidance for 2023. The company’s outlook for the full-year called for product revenue between $165 million– $170 million. Analysts were expecting the company to generate revenues of $193.3 million. The company’s Q4 results, released at the end of February, were also a mixed bag; product revenue reached $44.03 million, amounting to a 10.4% year-over-year increase and just edging ahead of the Street’s forecast. However, EPS of -$0.08 fell short of the -$0.06 expected on Wall Street.

The result is a stock down by 24% since the turn of the year – and 50% over the past 12 months.

Cathie Wood must see plenty to like here. Via her ARKK (Ark Innovation) and ARKG (ARK Genomic Revolution) funds, she has purchased 4,048,858 shares so far this year. Overall, she holds 12,150,378 shares via ARKK, and 5,970,211 shares via ARKG. Combined these are currently worth more than $50 million.

Mirroring Wood’s confidence, Cantor analyst Brandon Folkes sees more growth coming Cerus’ way.

“We believe adoption of the company’s Pathogen inactivation platelets is driving sustainable double-digit kit growth in the U.S.,” Folkes said. “For the long term, Cerus is developing Intercept-treated red blood cells, targeting a $2B market opportunity in North America and EMEA. In our view, near-term execution, as well as long-term development plans, which are well-in-motion, position CERS for potential significant upside. We expect the U.S. to drive near-to-medium-term growth, with the ex-U.S. opportunity to drive medium-to-long-term growth, and thus we remain confident about the sustained, long-term growth potential for CERS.”

To this end, Folkes rates the shares an Overweight (i.e., Buy), while his $9 price target.>
 
You must log in or register to reply here.
Back
Top